AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Can-Fite BioPharma will present its advanced stage drug pipeline at NobleCon21, including Phase III liver cancer, Phase IIa pancreatic cancer, and Phase III psoriasis trials. The company has $130 million in pharma licensing agreements and $325 million in veterinary agreements. CEO Motti Farbstein will conduct 1x1 meetings with investors. A high-definition video webcast will be available on the company's website and NobleCon website.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet